ICCC vs PETZ vs ELAN vs IDXX vs ZTS

For growth investors, TDH Holdings, Inc.

(PETZ) is the stronger pick with 122. 0% revenue growth year-over-year, versus 2. 3% for Zoetis Inc. (ZTS). TDH Holdings, Inc. (PETZ) offers the better valuation at 5. 6x trailing P/E, making it the more compelling value choice. Analysts rate Elanco Animal Health Incorporated (ELAN) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, TDH Holdings, Inc.

(PETZ) is the cheapest at 5. 6x versus IDEXX Laboratories, Inc. at 42. 8x. On forward P/E, Zoetis Inc. is actually cheaper at 11. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Zoetis Inc. wins at 0. 99x versus IDEXX Laboratories, Inc. 's 2. 68x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +6. 6%, compared to -97. 7% for TDH Holdings, Inc. (PETZ). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus PETZ's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TDH Holdings, Inc.

(PETZ) is the lower-risk stock at 0. 29β versus Elanco Animal Health Incorporated's 1. 46β — meaning ELAN is approximately 401% more volatile than PETZ relative to the S&P 500. On balance sheet safety, TDH Holdings, Inc. (PETZ) carries a lower debt/equity ratio of 13% versus 3% for Zoetis Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), TDH Holdings, Inc.

(PETZ) is pulling ahead at 122. 0% versus 2. 3% for Zoetis Inc. (ZTS). On earnings-per-share growth, the picture is similar: ImmuCell Corporation grew EPS 65. 3% year-over-year, compared to -169. 1% for Elanco Animal Health Incorporated. Over a 3-year CAGR, ICCC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

TDH Holdings, Inc.

(PETZ) is the more profitable company, earning 143. 8% net margin versus -8. 1% for ImmuCell Corporation — meaning it keeps 143. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ZTS leads at 38. 0% versus -146. 3% for PETZ. At the gross margin level — before operating expenses — ZTS leads at 70. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Zoetis Inc. (ZTS) is the more undervalued stock at a PEG of 0. 99x versus IDEXX Laboratories, Inc. 's 2. 68x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Zoetis Inc. (ZTS) trades at 11. 9x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 26. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ZTS: 61. 3% to $133. 57.

In this comparison, ZTS (2.

4% yield) pays a dividend. ICCC, PETZ, ELAN, IDXX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zoetis Inc.

(ZTS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 88), 2. 4% yield). Both have compounded well over 10 years (ZTS: +97. 8%, ELAN: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ICCC (Healthcare) and PETZ (Consumer Defensive) and ELAN (Healthcare) and IDXX (Healthcare) and ZTS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ICCC is a small-cap high-growth stock; PETZ is a small-cap high-growth stock; ELAN is a mid-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; ZTS is a mid-cap deep-value stock. ZTS pays a dividend while ICCC, PETZ, ELAN, IDXX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.